SR ONE Capital Management, LLC, 10% Owner at Odyssey Therapeutics, Inc. (ODTX), bought 747,096 shares at $18.00 ($10.0M) on 2026-05-11, disclosed to the SEC on 2026-05-11.
SR ONE Capital Management executed the largest insider purchase in Odyssey Therapeutics' history by buying 222,222 shares at $18.00 on May 11, 2026, signaling strong conviction in the biotech's prospects. This move comes as the stock trades near its 52-week low, potentially offering a value entry point for traders.
ODTX is currently trading at $17.23, sitting 14.62% below its 52-week high of $20.18 and 10.66% above its 52-week low of $15.57.
The stock debuted on May 11, 2026, trading lower despite raising $454 million in its IPO, which may present a short-term volatility opportunity. Additionally, the transaction represents the largest insider purchase in the company's history, potentially signaling a bottom in the stock.
The stock traded lower in its IPO debut on May 11, 2026, indicating weak market reception to the company's valuation. Furthermore, the insider sold once prior to this purchase, and industry buying activity has been negligible at 0.01% over the last 90 days.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 191,541 | $0 | 0.0% |
| 2 | $18.00 | 133,333 | $2.4M | 24.0% |
| 3 | $18.00 | 200,000 | $3.6M | 36.0% |
| 4 | $18.00 | 222,222 | $4.0M | 40.0% |
| Total | $13.39 avg | 747,096 | $10.0M | 100% |
| Filing → |
| ZBIO | BUY | 2025-10-14 | $2.4M | — | Filing → |
| ZBIO | BUY | 2024-09-16 | $30.5M | — | Filing → |
| DSGN | BUY | 2021-04-01 | $5.0M | — | Filing → |